drugset / Trial / NCT00865631

A Limited Food Effect Study of Gabapentin 800 mg Tablets

NCT00865631

Phase 1 Completed 18 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin Tablets by Purepac Pharmaceutical Co. with that of 400 mg (2 x 400 mg) NEURONTIN® by Parke-Davis following a single oral dose (1 x 800 mg tablet) or (2 x 400 mg capsules) in healthy adult male volunteers under non-fasting conditions, and will compare the differences in plasma levels after dosing the test formulation with and without food.

Timeline

Start
1999-06
Primary completion
1999-06
Completion
1999-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule 800 mg Oral

Indications

No indication recorded.